Remove 2017 Remove Clinical Development Remove Therapies
article thumbnail

Leniolisib

New Drug Approvals

2017, 8, 9, 975980 [link] The predominant expression of phosphoinositide 3-kinase (PI3K) in leukocytes and its critical role in B and T cell functions led to the hypothesis that selective inhibitors of this isoform would have potential as therapeutics for the treatment of allergic and inflammatory disease. World Health Organization (2017).

article thumbnail

PRITELIVIR MESYLATE

New Drug Approvals

It is currently in Phase III clinical development by the German biopharmaceutical company AiCuris Anti-infective Cures AG. US FDA granted fast track designation for pritelivir in 2017 and breakthrough therapy designation 2020. This is particularly important in immune compromised patients.

Virus 62
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

J&J, Legend Biotech Launch Rolling Submission for CAR-T Therapy for Multiple Myeloma | 2020-12-22

The Pharma Data

Legend will receive $75 million from J&J as a clinical development-based milestone payment, per a 2017 collaboration pact. Cilta-cel also won a Breakthrough Therapy designation in China in August. Source link.

article thumbnail

Cancer immunotherapy: GDF-15’s role in Anti-PD-1 resistance

Drug Target Review

Neutralising GDF-15 with CatalYm’s anti-GDF-15 antibody visugromab was shown to reverse its inhibitory effects and to re-sensitise tumours to anti-PD-1 treatment, achieving commensurate survival benefit of anti-GDF-15-anti-PD-1 combination therapy in vivo. in North America) in late 2017.

article thumbnail

Women in Stem with Dr Christine Schuberth-Wagner

Drug Target Review

I am currently working as Chief Scientific Officer at CatalYm, where we translate the latest scientific findings into clinical applications. Our company has identified a new role for Growth Differentiation Factor 15 (GDF-15) as a potent local immunosuppressor mediating cancer resistance to therapy. in North America) in late 2017.

Science 105
article thumbnail

Human neuronal cells: possibilities in drug safety testing

Drug Target Review

Early detection of neurotoxicity induced by potential new therapies is a major challenge, and hiPSC-neuronal cells may provide a solution. 1-4 This approach saves time, money, and resources, and ultimately leads to safer medicines going forward to the clinic. 2017 Jan;155(1):234–47. 2017 Jul 6;21(1):14–7. Toxicol Sci.

Drugs 111
article thumbnail

Identify and Validate Innovative Peptides for the Treatment of Obesity

The Pharma Data

This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. Financial terms of the new agreement are not disclosed.